

Greater Manchester and Oswestry Sarcoma Pathway Board Minutes of Meeting 28th January 2015

Christie NHS foundation Trust Oncology Seminar Room

Time: 2-4pm

Attendance	Representation
Dr JP Wylie	Chairman. Clinical oncologist Christie FT
Mr D Mowatt	Consultant in reconstructive surgeon Christie FT
Mr J Gregory	Consultant Surgeon , CMFT
Mr P Cool	RJAH Consultant Surgeon and MDT Chairman, RJAH FT
Miss Maxine Cumbo	Physiotherapy, CMFT
Caroline Pemberton	Sarcoma CNS RJAH FT
Hodan Noor	Pathway Manager, Manchester Cancer
Ann Buchan	Sarcoma CNS, Christie
Apologies	
Miss G Cribb	Consultant Surgeon, RJAH FT
Dr M Leahy	Medical oncologist/research and TYA representative Christie FT
Mr R Lalam	Bone Radiologist, RJAH FT
Anand Kirwadi	Consultant Radiologist, CMFT
Proff A. Freemont	Soft Tissue Pathologist, CMFT
Jane Evans	Sarcoma CNS RJAH FT
Helen Murray	Sarcoma CNS MRI
Dr P Shenjere	Soft tissue Pathologist Christie FT
Damian Heron	Director of North Wales Cancer Network

Agenda Item	Action
<p>1. Apologies</p> <p>Apologies were noted</p>	
<p>2. Minutes from the last meeting</p> <p>Members agreed minutes are an accurate reflection of the meeting.</p>	
<p>3. Matters Arising</p> <ul style="list-style-type: none"> - Comment on the draft ToR – Members has formally agreed the ToR HN to circulate the adopted version. - NW membership at the board has come to an end, formal thank you from the board. AK would be the natural replacement radiologist. However AK typically prepares the MDT meeting at the time of Board meetings and may find attendance difficult. 	<p>HN to circulate the adopted version.</p> <p>JW to speak to AK</p>
<p>4. Objective 1- Improving outcomes/survival rates</p> <ul style="list-style-type: none"> - CWP presentation – BW presented the Clinical Web Portal used at Christie’s with the board members. This portal focuses on collecting and measuring clinical outcomes and all referrals are made electronically in the MDT. Currently in the Manchester Cancer area Gynaecology pathway board is piloting this portal and Lung pathway will be in the second phase. BW proposed to send presentation and further information to the board. The members unanimously agreed this will benefit the pathway however would like further understanding on how this will link with existing performance systems and Somerset to avoid duplications. JW to make contact with JL and DS to request further information and support for the Sarcoma pathway to be part of the pilot. - Sarcoma UK golf ball Campaign update – HN and JW shared update with regards to Sarcoma UK Golf Ball campaign - co-branding is an option. Concerned expressed that this project has been on-going for many years in B’ham without obvious success. JW will speak to Rob Grimer to explore his views on this matter. HN shared the mapping requested in the last meeting on Lumps and bumps clinic across Greater Manchester. Members felt the need to discuss the benefits with the Golf Ball Campaign Lead, to explore benefits to engaging in the campaign. PC suggested Shropshire may be a good test area for this and consider auditing Shropshire GPs 2 week wait referrals before and after Golf Ball Challenge activated. PC to speak with Roger Wilson with regards to resourcing 50% of the cost per package, further costing needed for posting. PC to identify the number of GPs in Shropshire. - Manchester Cancer GP education update- education briefing has been shared further development with regards to engaging GPs and a planned education programme will be sent in due course. 	<p>JW to make contact with JL and DS to request further information and support for the Sarcoma pathway to be part of the pilot.</p> <p>JW to discuss the benefits with the Golf Ball Campaign Lead (Rob Grimer) , to explore benefits to engaging in the campaign</p> <p>PC to identify the number of GPs in Shropshire.</p>

<p>5. Objective 2- Improve Patient Experience</p> <ul style="list-style-type: none"> - Patient experience audit - awaiting AB for update. - Living with and Beyond Innovation fund applications was sent for information application was made by ML. - Sarcoma UK Gynaecology Sarcoma The Hidden Cancer report shared for information. 	
<p>6. Objective 3- Research and clinical innovation</p> <ul style="list-style-type: none"> - Clinical Trials report- shared for information, the NIHR team in Manchester will be using The Open Data Platform (ODP). The ODP integrates multiple data-sets in one place connecting research by bringing monitoring and performance data together. It currently provides secure access to study and recruitment information from Clinical Research Network Portfolio as well as key data from the Coordinated System for Gaining NHS Permissions (CSP). Each pathway will receive a yearly report with national comparisons and a quarterly report during the year. New plan is currently being developed by the new Research Manager Sue Dyde, in engaging research leads and nursing representatives. - A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma – new radiotherapy trial will be adopted. JW going to a workshop next week there will be a questionnaire to complete. 	
<p>7. Objective 4- Improving and standardising high quality care across the whole service</p> <ul style="list-style-type: none"> - Data quality update – DM will input operation data for Sarcoma from Jan 2014 for Christie to be registered. Operations and pathology codes have now been collected. Members have identify these codes does not support the clinical decisions and not relevant, the future development of CWP can potentially influence a more useful codes. - National Measure update – HN Has mapped the requirement of the NICE Quality Standards meeting with Data Manager to draft dash board including JWs request and the quality standards. - Referral guidelines and protocols- to be discussed at the next meeting 	<p>DM to start submitting operation details retrospectively from Jan 2014 onto SCR</p>
<p>8. A.O.B</p>	
<p>9. Date and time of the next meeting : 11 March 2 – 3.30pm, Christie FT, Trust Administration, Level 3, Room 6</p>	